Early-Stage Non-Small Cell Lung Cancer: Diagnostic Challenges and Therapeutic Innovations
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".
Deadline for manuscript submissions: 15 March 2026
Special Issue Editors
Interests: lung cancer; lung diseases; malignant pleural effusion; thoracic diseases; pulmonary medicine; interventional pulmonology; spirometry
Interests: pulmonology; syllabus; chronic obstructive lung disease
Special Issues, Collections and Topics in MDPI journals
2. Laboratory of Histology-Embryology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: asthma; lung cancer; biomarkers; airway remodeling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Early-stage non-small cell lung cancer (NSCLC) presents persistent diagnostic complexity despite advances in imaging and screening. Low-dose computed tomography (LDCT) has enhanced detection rates, yet differentiating indolent lesions from aggressive tumors remains challenging. Radiologic features alone are often insufficient, necessitating the integration of PET-CT, image-guided biopsy, and, increasingly, liquid biopsy and molecular profiling for accurate characterization.
Therapeutically, the landscape has evolved rapidly. Lobectomy via minimally invasive approaches remains the standard for operable patients, while stereotactic ablative radiotherapy (SABR) provides excellent local control (>90%) in those deemed medically inoperable. Recent data from trials such as ADAURA and IMpower010 support the incorporation of adjuvant targeted therapy (e.g., Osimertinib in EGFR-mutant disease) and immune checkpoint inhibitors, respectively, even in early-stage settings.
Precision oncology is now essential in the planning of treatment, with the integration of genomic and immunologic biomarkers informing both prognostication and therapeutic selection. Current clinical trials are aiming to refine neoadjuvant and adjuvant strategies, with ctDNA being employed to detect residual disease and stratify the risk of recurrence.
As our understanding of this disease is enhanced, early-stage NSCLC is shifting from a surgically focused paradigm to a multidisciplinary, biomarker-driven model of care.
Dr. Efimia Boutsikou
Dr. Georgia F. Hardavella
Dr. Kelly Domvri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer (NSCLC)
- early-stage lung cancer
- diagnostic imaging
- stereotactic ablative radiotherapy (SABR)
- molecular profiling
- adjuvant targeted therapy
- immunotherapy in early-stage NSCLC
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
